SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rise is being tied mainly to Morgan Stanley naming it a top pick, with traders highlighting AWS growth and AI opportunities such as Trainium, Bedrock and agentic commerce. Many are bullish on the rally, while others question whether it will last and point to heavy AI spending and uncertain returns as risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep slide toward fresh lows, with bearish traders citing possible continued dilution, upcoming filings, and doubts about Truth Socials engagement and business prospects. Political backlash over Trumps policies and midterm prospects dominates the broader debate, while some traders view the decline as a buying opportunity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention amid a sharp selloff as competing wet-AMD trial results shake confidence in retinal TKI therapies and raise questions about AXPAXLIs differentiation and commercial prospects. Traders disagree on whether competitor setbacks and Oculars positive SOL-1 results strengthen its position or whether lingering clinical and regulatory uncertainty outweighs its planned NDA filing.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is under pressure amid repeated analyst price-target cuts tied to soft residential roofing demand, a prolonged housing recovery, and higher costs, extending a steep slide toward new lows. Traders are divided between frustration over the selloff and managements limited communication, and long-term optimism about the acquisition strategy and eventual integration gains.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met both co-primary and all secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, addressing the FDAs earlier efficacy concerns; the company plans to resubmit its application. Traders are broadly positive on the results but debate the remaining regulatory path and dizziness reports, while others point to profit-taking and possible short-covering as the stock trades volatile.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent insider share purchases by the CEO and directors have fueled hopes of a rebound, with traders watching for a sustained move above a key technical level. Skeptics point to weakness in the core Celsius brand and say speculation about a Pepsi buyout is unconfirmed.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention after an earnings-driven rally, with traders pointing to a return to profitability and strong year-over-year revenue growth amid demand for InP substrates used in AI data-center optics. Bulls see room for growth, while skeptics argue the valuation is stretched and the stock remains highly volatile.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and repeated underperformance versus Bitcoin are driving attention, with traders pointing to doubts about its AI/data-center pivot and the lack of signed tenant leases alongside criticism of management and shareholder dilution. Some are buying the sharp dip or anticipating a short squeeze, but bearish traders see continued downside absent a contract or stronger Bitcoin-linked gains.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

XERSs sharp rally and breakout above its prior high are fueling takeover speculation, especially chatter about Lundbeck and a possible bidding war, though no deal is confirmed and some traders doubt the rumors. Others point to revenue growth and the XP-8121 pipeline as support for the companys prospects independent of a sale.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention ahead of its quarterly results, with traders focused on margins and profitability despite strong deliveries; bullish bets on the recent rally and an earnings move contrast with bearish expectations of a miss. The Roadster reveal has also fueled speculative SpaceX-merger chatter, though traders disagree about its business significance and whether a deal is likely.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Equity

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.


Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.


Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.


iShares Trust - iShares Morningstar Small-Cap ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The company plans to begin its global late-stage program in moderate-to-severe atopic dermatitis by the end of July 2026.</li><li>In alopecia areata, a condition that causes hair loss, Nektar reported positive results from its mid-stage study in April 2026.</li><li>In the second half of 2026, Nektar also plans to present more data from its mid-stage eczema study, particularly how well improvements are sustained on lowered dosing.</li></ul><p>Shares of Nektar Therapeutics (NKTR) jumped 10% on Thursday as investors await updates on its lead candidate, rezpegaldesleukin, being developed for autoimmune and inflammatory diseases.</p><p>The company has multiple near-term catalysts in place, some expected as early as this month. The stock posted its best day since April on Thursday. &nbsp; &nbsp;</p><h2 class="st-heading-2">NKTR’s Atopic Dermatitis Program</h2><p>The company plans to begin its global late-stage program in moderate-to-severe atopic dermatitis by the end of July 2026. The studies will test a specific dose given every two weeks for the first six months, followed by less frequent maintenance doses. They will include both patients who have never tried biologic medicines and those who have already used them. The goal is to gather the data needed for regulatory approval, with the first results expected around mid-2028.</p><h2 class="st-heading-2">Progress In Alopecia Areata</h2><p>In alopecia areata, a condition that causes hair loss, Nektar reported positive results from its mid-stage study in April 2026. These findings showed stronger responses in patients with severe disease. The company then said that it plans to meet with the FDA in the second quarter of 2026 to discuss plans for larger late-stage trials. Additional data from patients who stopped treatment will be released in the fourth quarter of this year.</p><h2 class="st-heading-2">Other Catalysts</h2><p>A longer-term update showing results from patients one year after they stopped taking the drug in the eczema study is expected in the first quarter of 2027. This could indicate whether the treatment provides lasting benefits even after therapy ends.</p><p>In the second half of 2026, Nektar also plans to present more data from its mid-stage eczema study, particularly how well the improvements are sustained on lowered dosing, and begin an early study in at least one new disease area beyond atopic dermatitis, alopecia areata, and Type 1 diabetes.</p><p>Nektar ended the first quarter of 2026 with more than one billion dollars in cash and investments after a public offering. This strong financial position gives the company runway well into 2028 to advance its lead drug without needing immediate new funding, it previously said.</p><h2 class="st-heading-2">How Did NKTR Retail Traders React?</h2><p>On Stocktwits, retail sentiment around NKTR stock jumped from 'bearish' to 'bullish' territory over the past 24 hours, while message volume stayed at 'high' levels.</p><p>A Stocktwits user opined that momentum is building in NKTR stock.</p><p><stembedurl>https://www.stocktwits.com/FibonacciFortress/message/658228663</stembedurl></p><p>Another refuted the opinion, saying that there have not been many announcements from the company in recent weeks. “Quiet tape, fading catalysts, cold momentum,” they wrote.&nbsp;</p><p><stembedurl>https://www.stocktwits.com/FutureBulls/message/658197825</stembedurl></p><p><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> has gained 68% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-ends-higher-why-this-strategist-picks-biogen-over-other-biotech-peers/cZm7GYQR7jB">BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.

iShares Morningstar Small-Cap ETF

iShares Core S&P Total U.S. Stock Market ETF

Nektar Therapeutics

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$70.58
Prev Close	$70.68
Open	$70.58
Dividend Yield	N/A
50-Day Moving Average	$73.92
Beta	N/A
Avg. Volume	5,309.22
PE Ratio	N/A

52-Week High	$77.55
52-Week Low	$60.51
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

ISCB Fundamentals